Summit Therapeutics (SMMT) Cash & Equivalents (2017 - 2026)

Summit Therapeutics (SMMT) has reported Cash & Equivalents for 10 consecutive years, with $419.4 million the latest figure, recorded in Q2 2026.

• Quarterly Cash & Equivalents rose 40.79% year-over-year to $419.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $419.4 million (up 40.79% YoY) and the FY2025 annual result came in at $225.3 million, up 114.82% from the prior year.
• Cash & Equivalents rose to $419.4 million in Q2 2026 per SMMT's latest filing, from $106.5 million in the prior quarter.
• Over the last five years, Cash & Equivalents for SMMT reached as high as $419.4 million in Q2 2026 and fell as low as $23.8 million in Q3 2023.
• A 5-year average of $154.1 million and a median of $105.7 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 80.49% — and 2025, when it soared 947.59%.
• Year by year, Cash & Equivalents stood at $348.6 million in 2022, then tumbled by 79.51% to $71.4 million in 2023, then soared by 46.81% to $104.9 million in 2024, then surged by 114.82% to $225.3 million in 2025, then jumped by 86.16% to $419.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $419.4 million, $106.5 million, and $225.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.